After delivering one of its strongest quarters ever, pharmaceutical major Lupin Ltd. is preparing for the next leg of growth, anchored in complex generics, respiratory therapies, and targeted speciality acquisitions, while maintaining a firm grip on profitability and capital discipline.

The company reported a 24 per cent year-on-year rise in revenue in the second quarter of FY26 to ₹6,831 crore, driven by strong gains in the United States and emerging markets. EBITDA rose 76 per cent to ₹2,431 crore, with margins improving to 35.6 per cent, while profit after tax grew 73 per cent to ₹1,485 crore. Advertisement

“We have been steadily improving our performance over the last several quarters,” said Ramesh Swaminathan, Executive Director and Global CFO, Lupin. “This is on the back of severa

See Full Page